# Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

> **NCT01568775** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 12 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Aliskiren

## Key facts

- **NCT ID:** NCT01568775
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568775, "Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01568775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*